Massachusetts Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center

• Category: Corporations - Public - Licenses
• State: Multi-State
• Control #: US-EG-9161
• Format: Word; Rich Text

Description

Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages The Massachusetts Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a comprehensive and legally-binding agreement that outlines the terms and conditions for the licensing of collateral rights related to specific intellectual property (IP) owned by the University, in order to facilitate the commercialization of the technology by Gentling, Inc. This agreement is executed with the aim of promoting research and development, promoting entrepreneurship, and fostering innovation and economic growth. Under this agreement, Gentling, Inc. is granted a non-exclusive license to use the University's IP for commercial purposes, subject to certain conditions and limitations. The license includes the rights to produce, market, sell, and distribute products or services that are based on or incorporate the intellectual property subject to the agreement. The Massachusetts Collateral License Agreement also establishes the scope of the licensed IP, defining the specific rights and restrictions associated with its use. It typically includes provisions related to the ownership of intellectual property, confidentiality of proprietary information, indemnification for potential infringement claims, and the procedures for dispute resolution. While the general structure and core provisions of the Massachusetts Collateral License Agreement remain consistent, there may be different types or variations of the agreement depending on various factors such as the specific technology or IP being licensed, the duration of the agreement, royalty or payment structures, and any additional provisions negotiated between the parties involved. For instance, there might be different versions of the agreement specific to certain fields of research or technology, such as biotechnology, pharmaceuticals, medical devices, or software. These variations would address specific considerations unique to each field and tailor the agreement accordingly. Furthermore, the Massachusetts Collateral License Agreement may also include provisions for sublicensing or subletting the licensed IP to third parties, subject to the approval of the University. This allows Gentling, Inc. to further propagate the technology and maximize its potential impact on the market. In conclusion, the Massachusetts Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a vital legal instrument that governs the licensing of intellectual property rights to promote commercialization and technological advancements. Its various types and versions cater to the unique characteristics of different technologies, facilitating fruitful collaborations between academia and industry.

The Massachusetts Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a comprehensive and legally-binding agreement that outlines the terms and conditions for the licensing of collateral rights related to specific intellectual property (IP) owned by the University, in order to facilitate the commercialization of the technology by Gentling, Inc. This agreement is executed with the aim of promoting research and development, promoting entrepreneurship, and fostering innovation and economic growth. Under this agreement, Gentling, Inc. is granted a non-exclusive license to use the University's IP for commercial purposes, subject to certain conditions and limitations. The license includes the rights to produce, market, sell, and distribute products or services that are based on or incorporate the intellectual property subject to the agreement. The Massachusetts Collateral License Agreement also establishes the scope of the licensed IP, defining the specific rights and restrictions associated with its use. It typically includes provisions related to the ownership of intellectual property, confidentiality of proprietary information, indemnification for potential infringement claims, and the procedures for dispute resolution. While the general structure and core provisions of the Massachusetts Collateral License Agreement remain consistent, there may be different types or variations of the agreement depending on various factors such as the specific technology or IP being licensed, the duration of the agreement, royalty or payment structures, and any additional provisions negotiated between the parties involved. For instance, there might be different versions of the agreement specific to certain fields of research or technology, such as biotechnology, pharmaceuticals, medical devices, or software. These variations would address specific considerations unique to each field and tailor the agreement accordingly. Furthermore, the Massachusetts Collateral License Agreement may also include provisions for sublicensing or subletting the licensed IP to third parties, subject to the approval of the University. This allows Gentling, Inc. to further propagate the technology and maximize its potential impact on the market. In conclusion, the Massachusetts Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a vital legal instrument that governs the licensing of intellectual property rights to promote commercialization and technological advancements. Its various types and versions cater to the unique characteristics of different technologies, facilitating fruitful collaborations between academia and industry.